KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biolife Solutions (BLFS) Net Cash Flow (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Net Cash Flow for 16 consecutive years, with $3.6 million as the latest value for Q4 2025.

Quarterly Net Cash Flow fell 95.0% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$62.3 million through Dec 2025, down 204.0% year-over-year, with the annual reading at -$62.3 million for FY2025, 204.0% down from the prior year.
Net Cash Flow for Q4 2025 was $3.6 million at Biolife Solutions, up from -$2.4 million in the prior quarter.
The five-year high for Net Cash Flow was $71.2 million in Q4 2024, with the low at -$35.3 million in Q2 2022.
Average Net Cash Flow over 5 years is -$2.9 million, with a median of -$2.3 million recorded in 2023.
The sharpest move saw Net Cash Flow tumbled 2797.92% in 2021, then skyrocketed 407.94% in 2022.
Over 5 years, Net Cash Flow stood at -$5.4 million in 2021, then plummeted by 41.34% to -$7.7 million in 2022, then surged by 310.25% to $16.1 million in 2023, then surged by 341.96% to $71.2 million in 2024, then tumbled by 95.0% to $3.6 million in 2025.
According to Business Quant data, Net Cash Flow over the past three periods came in at $3.6 million, -$2.4 million, and -$35.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.